All In Biotech

Drug Trial Radar · NCT05218499

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Mar 31, 2022

Primary completion

Apr 16, 2024

Study completion Jan 26, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to people with a type of cancer called dedifferentiated liposarcoma. People with advanced liposarcoma aged 18 or older who are not receiving any other cancer treatment can participate. The purpose of this study is to compare a medicine called brigimadlin (BI 907828) with doxorubicin in people with liposarcoma. Brigimadlin (BI 907828) is a so-called MDM2 inhibitor that is being developed to treat cancer. Doxorubicin is a medicine already used to treat cancer including liposarcoma. During the study, participants get either brigimadlin (BI 907828) or doxorubicin. Every 3 weeks, participants take brigimadlin (BI 907828) as tablets or doxorubicin as an infusion into a vein. Participants can switch to brigimadlin (BI 907828) treatment if they did not benefit from doxorubicin treatment. Participants can continue treatment in the study as long as they benefit from it and can tolerate it. Doctors regularly check the size of the tumour and check whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Liposarcoma, Dedifferentiated

Interventions

  • BrigimadlinDrug

    Brigimadlin taken orally on day 1 of each 21-day cycle (q3w).

  • DoxorubicinDrug

    Intravenous infusion of 75 milligram per square meter (mg/m2) on Day 1 of each 21-day cycle (q3w) until a maximum cumulative dose of 450 mg/m2 (approximately 6 cycles).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to 20.6 months.

Locations

109 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Arizona

    Tucson, Arizona

  • Precision NextGen Oncology

    Beverly Hills, California

  • City of Hope-Duarte-56419

    Duarte, California

  • University of Southern California

    Los Angeles, California

  • Sarcoma Oncology Center

    Santa Monica, California

  • Mayo Clinic Cancer Center

    Jacksonville, Florida

  • Winship Cancer Institute

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Mayo Clinic, Rochester

    Rochester, Minnesota

  • Barnes-Jewish Hospital

    St Louis, Missouri

  • Nebraska Cancer Specialists-Omaha-69502

    Omaha, Nebraska

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Oregon Health and Sciences University

    Portland, Oregon

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Froedtert and The Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Prince of Wales Hospital-Randwick-66496

    Randwick, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Ashford Cancer Centre Research

    Kurralta Park, South Australia, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • UZ Leuven

    Leuven, Belgium

  • BC Cancer Agency - Vancouver

    Vancouver, British Columbia, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Maisonneuve-Rosemont Hospital

    Montreal, Quebec, Canada

  • Cancer Hospital of Chinese Academy of Medical Science

    Beijing, China

  • Beijing Cancer Hospital

    Beijing, China

  • The First Hospital of Jilin University

    Changchun, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • Sun Yat-Sen University Cancer Center

    Guangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Zhongshan Hospital Affiliated to Fudan University

    Shanghai, China

  • Wuhan Union Hospital

    Wuhan, China

  • Masaryk Memorial Cancer Institute

    Brno, Czechia

  • University Hospital Olomouc

    Olomouc, Czechia

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.